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Abstract 
Obstructive sleep apnea (OSA), independently of obesity (OBS), predisposes to insulin 
resistance (IR) for largely unknown reasons. Because OSA-related intermittent hypoxia 
triggers lipolysis, overnight increases in circulating free fatty acids (FFAs) including 
palmitic acid (PA) may lead to ectopic intramuscular lipid accumulation potentially con-
tributing to IR. Using 3-T-1H-magnetic resonance spectroscopy, we therefore compared 
intramyocellular and extramyocellular lipid (IMCL and EMCL) in the vastus lateralis 
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(17 obese, 9 nonobese) and 23 healthy male controls (12 obese, 11 nonobese). Fiber 
type composition was evaluated by muscle biopsies. Moreover, we measured fasted 
FFAs including PA, glycated hemoglobin A1c, thigh subcutaneous fat volume (ScFAT, 1.5-T 
magnetic resonance tomography), and maximal oxygen uptake (VO2max). Fourteen pa-
tients were reassessed after continuous positive airway pressure (CPAP) therapy. Total 
FFAs and PA were significantly (by 178% and 166%) higher in OSA patients vs controls 
and correlated with the apnea-hypopnea index (AHI) (r ≥ 0.45, P < .01). Moreover, IMCL 
and EMCL were 55% (P < .05) and 40% (P < .05) higher in OSA patients, that is, 114% and 
103% in nonobese, 24.4% and 8.4% in obese participants (with higher control levels). 
Overall, PA, FFAs (minus PA), and ScFAT significantly contributed to IMCL (multiple 
r = 0.568, P = .002). CPAP significantly decreased EMCL (–26%) and, by trend only, IMCL, 
total FFAs, and PA. Muscle fiber composition was unaffected by OSA or CPAP. Increases 
in IMCL and EMCL are detectable at approximately 7 am in OSA patients and are partly 
attributable to overnight FFA excesses and high ScFAT or body mass index. CPAP de-
creases FFAs and IMCL by trend but significantly reduces EMCL.
Key Words: ectopic fat, intermittent hypoxia, diabetes, obesity, aerobic capacity
Obstructive sleep apnea syndrome (OSA) and obesity 
(OBS) are closely associated conditions that both impose 
severe metabolic as well as cardiovascular risks [1-6]. The 
prevalence of moderate to severe OSA (as defined by an 
apnea-hypopnea index [AHI] > 15  h–1) in male adults 
aged 50 to 70 years reaches at least 17% and is largely de-
pendent on OBS, that is, it increases to an alarming 29.9% 
or even 56% with a body mass index (BMI) of 30 to 40 
or greater than 40 kg m−2, respectively [7-9]. According to 
a more recent large, community-based study, these num-
bers may still represent an underestimation [10]. OBS is 
considered to promote OSA directly via parapharyngeal or 
thoracic fat or indirectly through increases in circulating 
cytokines, insulin, or leptin as implicated in impaired sleep 
quality/quantity and ventilatory control [2, 11, 12]; by con-
trast, OSA-related sleep fragmentation and chronic inter-
mittent hypoxia (CIH) may contribute to weight gain and 
metabolic disorders possibly involving novel factors like 
peripheral chemoreceptor dysfunction. Despite such com-
plex interaction with OBS, OSA independently predisposes 
to hypertension [13], increased carotid intima media thick-
ness (cIMT) [14], coronary heart disease [15, 16], myocar-
dial infarction [17], stroke [18-20], or death [4, 5]. More 
recently, an OBS-independent association between OSA 
and insulin resistance (IR) and type 2 diabetes [2, 6, 21] 
was shown to be causal by a randomized controlled trial 
demonstrating that IR was significantly improved through 
(supervised) 8 hours of continuous positive airway pressure 
(CPAP) per night [22]. However, the common adherence of 
4 hours CPAP per night under real-world conditions may 
not have a significant benefit for IR [1, 19, 23, 24].
Until now, the specific link between OSA and IR 
has remained unclear and obscured by a large overlap 
of OSA- and OBS-associated factors of IR like the 
proinflammatory/oxidative milieu [25-27], dyslipidemia, 
and hepatic steatosis [28]. OSA may, however, involve 
OBS-independent, unique pathophysiological triggers 
through CIH, sympathetic activation, periodic sways 
in intrathoracic and O
2/CO2 partial pressures, and sleep 
fragmentation. These factors result in massive increases 
in circulating catecholamines, atrial natriuretic peptide, 
and angiotensin II [1, 2], low nitric oxide availability, for 
example, via low endothelial NO synthetase expression, 
increased nitrotyrosine formation [27, 29], in addition to 
increases in vascular endothelial growth factor expres-
sion [30, 31]. Therefore, the mechanisms with OSA and 
OBS leading to IR, dyslipidemia, and inflammation may 
be different, as illustrated by the separate or combined ef-
fects of CPAP and weight loss intervention [23]. Indeed, 
IR could be experimentally induced in lean healthy volun-
teers through 5 hours of CIH corresponding to an AHI 
of 24.3  h–1 [32-34]. In lean mice, IR could be triggered 
by sleep fragmentation [35], and IR caused by CIH was 
successfully prevented by alpha-adrenergic (but not beta-
adrenergic) blockade [36, 37]. The increase of circulating 
catecholamines through exaggerated and repetitive sym-
pathetic activation (especially with OSA-related long-term 
facilitation of the peripheral (carotid) O2 chemoreflex) 
may well result in excessive lipolysis [38] as demonstrated 
by numerous peaks in plasma free fatty acids (FFAs) 
during the first 4 hours of sleep in OSA patients on inter-
ruption of CPAP therapy [39]. Earlier studies already dem-
onstrated that OSA-related FFA increases can be prevented 
by oxygen supply in patients with heart failure [40] and 
that FFA infusion in lean individuals caused skeletal lipid 






/jes/article/5/8/bvab082/6270600 by E-Library Insel user on 27 July 2021
3  Journal of the Endocrine Society, 2021, Vol. 5, No. 8
It was therefore hypothesized by Gu et al [38] that OSA 
could trigger a “perfect storm” of FFAs, leading to ectopic 
lipid accumulation in skeletal muscle fibers (in addition to 
endothelium and hepatocytes), where it is an established 
factor of peripheral IR [42, 43]. Increased intramyocellular 
lipid (IMCL) may indeed lead to decreases in insulin 
signaling to protein kinase B, mitochondrial density, and 
function among other metabolic perturbations that are 
considered to be in line with a “lipotoxic” concept, or 
the more recent, “gridlock” theory of IR, an insufficient 
switching between competing, overloaded substrates [44-
46]. Moreover, increases in extramyocellular lipid (EMCL) 
may also become critical for IR, as EMCL may recruit in-
flammatory cells, especially macrophages, expressing para-
crine factors of IR like tumor necrosis factor (TNF) [47, 
48]. TNF along with other inflammatory cytokines may 
impair microvascular regulation and therefore the delivery 
of insulin and glucose to myofibers (the “microvascular” 
concept of IR) [49].
To date, studies on IMCL and EMCL in OSA are rare 
and limited to 1.5-Tesla (T) 1H-magnetic resonance spec-
troscopy (1H-MRS), which provides rather limited separ-
ation of IMCL and EMCL signals. A recent cross-sectional 
study showed significantly lower IMCL and EMCL of the 
vastus lateralis muscle in patients with severe OSA and im-
paired glycemic control as compared to healthy controls 
[50]. A previous 1.5 T 1H-MRS study detected no differ-
ence in either IMCL or insulin sensitivity in obese OSA pa-
tients under regular CPAP treatment compared to irregular 
CPAP treatment use over 12 weeks [51].
In our study we hypothesized, in line with others [38, 42, 
43], that using 3-T 1H-MRS and taking measures at around 
7 am, that is, immediately after overnight lipolytic episodes, 
will allow us to detect significant increases of IMCL and 
EMCL (primary outcome) in OSA patients compared to 
healthy controls that might be related to higher circulating 
FFA levels. In addition to this cross-sectional comparison 
we also evaluated whether 3 to 5 months of home-based 
CPAP would affect (normalize) IMCL, EMCL, and FFAs. 
Muscle biopsies were obtained to control for fiber type 
composition in both the cross-sectional and the longitu-
dinal comparison, as the lipid content has been shown to 
depend on fiber type [52].
Materials and Methods
Study Population and Design
Twenty-six male patients with hitherto untreated moderate 
to severe OSA (AHI > 15 h–1) were recruited from the out-
patient clinic of the Department of the Sleep Medicine of the 
University Clinics of Marburg after home cardiorespiratory 
polygraphy for eligibility. The patients were assigned to an 
obese stratum (BMI ≥ 30 kg m−2, n = 17; BMI range, 30.0-
36.6 kg m−2) or to a nonobese stratum with or without 
overweight (BMI < 30 kg m−2, n = 9; BMI range: 21.0-28.4 
kg m−2) (Table 1). Twenty-three healthy men of similar age 
without a history of snoring or sleep apnea were recruited 
by public announcement to an obese control stratum 
(n = 12; BMI range, 30.0-38.0 kg m−2) or to a nonobese 
control stratum with or without overweight (n = 11; BMI 
range: 21.1-29.4 kg m−2) (see Table 1). Prior to inclusion 
all participants underwent 2 overnight polysomnographies 
in the hospital to assess the severity of OSA. After an over-
night fast (second stationary night), all participants under-
went 3-T 1H-MRS for IMCL and EMCL at around 7 am 
and provided a venous blood sampling between 7 and 
9  am. At least 2 hours after breakfast, the participants’ 
right thigh subcutaneous fat volume (ScFAT) was deter-
mined by 1.5-T magnetic resonance tomography and their 
maximal oxygen uptake (VO2max) was measured. Muscle 
biopsies were obtained several hours thereafter (to allow 
for blood flow normalization). Any study-related delay in 
the initiation of CPAP therapy was excluded by individual 
adjustments in the time schedule for outpatients. Fourteen 
OSA patients agreed to a longitudinal evaluation after 3 to 
5  months of home-based CPAP therapy on the variables 
IMCL, EMCL, blood parameters, VO2max, and muscle 
biopsy histomorphometry. Informed oral and written con-
sent was obtained from all participants. This study was ap-
proved by the local ethical committee of the medical faculty 
(FB20) of the University of Marburg (63/11, September 12, 
2011) and complied with good laboratory and medical 
practice and the amended Declaration of Helsinki (1996).
All participants underwent an initial medical assessment 
that included a detailed medical history including physical 
activity, physical examination, postabsorptive venous rou-
tine blood parameters, bilateral brachial blood pressure 
measurement by the Riva-Rocci method after 20 minutes 
of rest, ultrasonic measurement of cIMT by the Logiq E9 
system and 9D-L-scanner (GE), pulmonary function, and a 
12-lead electrocardiogram at rest.
VO2max was assessed by an incremental cycle ergom-
eter test using the Ergoline 100 system with workload 
increments of 25 W every 2 minutes starting from 50 W 
until exhaustion. VO2max was calculated as the max-
imum of mean values covering intervals of 10 seconds 
using the ZAN 680 breath-by-breath spirometry system 
(ZAN Ferraris Cardiorespiratory) for measurement of 
tidal volume, breathing frequency, as well inspiratory and 
end-tidal gas fractions. Continuous measurements of this 
system furthermore included a 12-lead electrocardiogram 
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Exclusion criteria: Age younger than 35 or older than 
65 years; smoking or any history of smoking; any medica-
tion; any vitamin or antioxidant supplementation; central 
or mixed sleep apnea determined by polysomnography; 
prior CPAP treatment; type 2 diabetes mellitus or glycated 
hemoglobin  A1c (HbA1c) greater than 7.0; preexisting ar-
terial hypertension or a resting (20 minutes) systolic bra-
chial arterial blood pressure of more than 180 or diastolic 
of greater than 115 mm Hg; any known cardiac, respira-
tory, or other internal, neurological or psychiatric, im-
munological, or inflammatory diseases; any alcohol or 
drug abuse; missing written consent; or any reported 
coagulopathy or susceptibility to keloid development with 
regard to skin incision for muscle biopsy.
Inpatient Polysomnography
The polysomnography on 2 consecutive nights was per-
formed at the nationally licensed Department of Sleep 
Medicine, University Clinics of Marburg, using the 
SIDAS-GS-System (Fa. Stimotron Medizinische Geräte 
GmbH). The first night was to familiarize the partici-
pants with the equipment and the environment. Data 
obtained during the second night were used to determine 
Table 1. Anthropometry, polysomnography, vascular risk factors, free fatty acids, intramyocellular lipid content and 
extramyocellular lipid content as well as maximal oxygen uptake and physical activity of untreated obstructive sleep apnea 
patients and controls and their respective nonobese and obese strata
 All Nonobese Obese
ANOVAControl OSA Control OSA Control OSA
No. 23 26 11 9 12 17 49
Age y 45.4 ± 1.2 48.8 ± 1.4 45.0 ± 1.7 52.2 ± 1.7b 45.8 ± 1.7 47.0 ± 1.7d a
Body ht cm 180.2 ± 1.2 176.2 ± 3.0 182.1 ± 1.8 180.0 ± 2.5 178.5 ± 1.6 174.2 ± 4.4  
Body wt kg 94.4 ± 2.5 102.1 ± 4.5 84.3 ± 1.8 83.1 ± 2.8 103.7 ± 2.3f 112.2 ± 5.3f f
BMI kg m−2 29.3 ± 0.9 30.9 ± 0.9 25.8 ± 0.7 25.6 ± 0.8 32.5 ± 0.6f 33.7 ± 0.5f f
Subcutaneous fat, thigh cm3 3766 ± 279 4064 ± 226 2693 ± 181 3050 ± 242 4481 ± 307 4605 ± 218 f
AHI h–1 5.3 ± 0.8 48.8 ± 4.6c 5.8 ± 1.3 41.8 ± 6.8c 4.8 ± 1.0 52.8 ± 6.1c c
Time < 90% SaO2 min 1.86 ± 0.79 64.5 ± 15.0
c 0.81 ± 0.43 47.32 ± 17.46b 2.82 ± 1.43 73.6 ± 21.0c c
Mean SaO2 % 94.3 ± 0.2 92.5 ± 0.4
b 94.2 ± 0.2 92.9 ± 0.5a 94.3 ± 0.3 92.2 ± 0.5b c
Heart rate at rest min–1 64.8 ± 2.0 72.0 ± 2.2a 68.5 ± 3.3 70.4 ± 4.7 61.4 ± 2.0 72.9 ± 2.4a a
BP systolic mm Hg 137.5 ± 2.0 146.6 ± 3.4a 136.0 ± 1.4 136.8 ± 5.5 138.8 ± 2.7 151.6 ± 3.1a,d a,d
BP diastolic mm Hg 88.0 ± 1.1 94.4 ± 2.0b 86.9 ± 1.5 89.6 ± 3.2 89.0 ± 1.7 97.1 ± 2.3b a,d
cIMT mm 0.62 ± 0.02 0.70 ± 0.03a 0.61 ± 0.03 0.71 ± 0.06 0.63 ± 0.03 0.70 ± 0.03 a
HbA1c % 5.50 ± 0.05 5.70 ± 0.08
a 5.48 ± 0.06 5.71 ± 0.06a 5.50 ± 0.09 5.70 ± 0.12 a
Glucose, fasted mg 100 mL–1 92.3 ± 1.5 98.5 ± 2.5a 93.3 ± 1.9 98.0 ± 4.3 91.3 ± 2.3 98.8 ± 3.1  
Insulin, fasted µU mL–1 7.69 ± 1.25 12.35 ± 1.51a 5.45 ± 0.98 8.64 ± 2.12 9.93 ± 2.15 14.21 ± 1.88 d
HOMA-IR  1.77 ± 0.30 3.04 ± 0.39a 1.24 ± 0.22 2.15 ± 0.59 2.30 ± 0.53 3.48 ± 0.47 a,d
TNF, circulating pg mL–1 9.01 ± 1.16 6.93 ± 0.28 8.93 ± 2.27 7.56 ± 0.66 9.08 ± 0.74 6.58 ± 0.19b  
HDL mg 100 mL–1 48.3 ± 2.0 42.8 ± 2.7 51.5 ± 3.2 42.9 ± 2.5 45.3 ± 2.3 42.8 ± 4.0  
LDL mg 100 mL–1 138.4 ± 6.6 138.2 ± 9.6 153.7 ± 6.4 147.0 ± 17.2 124.4 ± 9.7d 133.3 ± 11.6  
Total cholesterol mg 100 mL–1 203.3 ± 8.0 214.1 ± 7.8 219.6 ± 8.9 229.0 ± 15.2 188.4 ± 11.1d 205.8 ± 8.3 d
Triglycerides mg 100 mL–1 110.1 ± 12.7 165.8 ± 21.5 95.6 ± 12.6 214.7 ± 40.9a 123.3 ± 21.2 138.4 ± 22.7 a,g
Total FFAs, C12-C24 mg mL–1 5.29 ± 0.31 14.72 ± 3.33b 5.05 ± 0.33 16.95 ± 6.75a 5.51 ± 0.53 13.54 ± 3.76 a
Palmitic acid, 16:0 mg mL–1 1.11 ± 0.07 2.96 ± 0.67a 1.02 ± 0.07 3.47 ± 1.37a 1.21 ± 0.12 2.69 ± 0.74 a
IMCL a.u. 13.55 ± 2.03 21.06 ± 2.68a 9.06 ± 1.15 19.36 ± 3.91a 17.66 ± 3.39d 21.97 ± 3.61 a
EMCL a.u. 15.89 ± 2.39 22.22 ± 2.04a 11.81 ± 1.80 24.00 ± 3.83b 19.64 ± 4.07 21.28 ± 2.44 a
VO2max l min
–1 3.24 ± 0.13 2.79 ± 0.16a 3.51 ± 0.16 2.43 ± 0.27b 2.94 ± 0.18d 2.95 ± 0.20 a,g
VO2max/kg mL min
–1 kg–1 35.4 ± 2.1 28.5 ± 1.5b 41.9 ± 2.5 29.5 ± 3.2b 28.3 ± 1.6f 28.0 ± 1.6 b,e,h
Physical activity h wk–1 2.59 ± 0.63 1.00 0.27a 3.86 ± 0.24 1.11 ± 1.76 1.42 ± 0.50 0.94 ± 0.30 a,d
Data represent mean ± SEM. 
Abbreviations: AHI, apnea-hypopnea index; ANOVA, analysis of variance; a.u., arbitrary units; BMI, body mass index; BP, brachial arterial blood pressure; cIMT, 
carotid intima media thickness; EMCL, extramyocellular lipid content; FFAs, free fatty acids; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; 
HOMA-IR, homeostasis assessment model index of insulin resistance (see “Materials and Methods”); IMCL, intramyocellular lipid content; LDL, low-density 
lipoprotein; OSA, obstructive sleep apnea; SaO2, oxygen saturation; TNF, tumor necrosis factor; VO2max, maximal oxygen uptake with or without normalization 
for body weight in kg.
aP less than .05; bP less than .01; cP less than .001 OSA vs control.
dP less than .05; eP less than .01; fP less than .001 obese vs nonobese.
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AHI (during total sleep time) of obstructive, central ner-
vous, or mixed origin, arousal index (n/h total sleep time) 
mean, and minimal O2 saturation (SaO2) in rapid eye 
movement (REM) or non-REM sleep phases, cumulative 
time (minutes) spent at SaO2 less than 90% (Tu90%), less 
than 80% or less than 70% as well as time (minutes) and 
fraction (%) of sleep stages in REM and non-REM (1, 2 
or 3, 4) among other parameters. On night 3 or 4 at the 
sleep center (ie, after baseline measurements within this 
study), the OSA patients were introduced to optimized 
CPAP treatment. After 3 to 5  months of home-based 
CPAP treatment, 14 OSA patients were reevaluated in the 
hospital regarding their treatment effectiveness and com-
pliance before reassessment of study parameters.
Venous Blood Parameters
Antecubital venous blood samples were obtained 
after an overnight fast and routinely processed by the 
Central Laboratory of the University Clinics of Marburg 
for plasma levels of HbA1c (HPLC, Tosoh G8, Tosoh 
Bioscience), glucose, as well as insulin (Cobas  8000, 
Roche) for calculation of the homeostasis model assess-
ment index of IR (HOMA-IR, “insulin (µU/mL) × glucose 
(mg/100 mL)/405”), furthermore, triglycerides, total chol-
esterol, low-density lipoprotein, high-density lipoprotein, 
as well as other routine laboratory screening parameters 
for hepatic, renal, and muscular diseases (AU5800 chem-
istry analyzers, Beckman Coulter), myoglobin, total plasma 
homocysteine, thyrotropin, 3,5,3′-triiodothyronine, and 
thyroxine (DxI 800, Beckman Coulter), hemoglobin, hem-
atocrit, and differential hemogram (XN system, Sysmex) 
as well as TNF (Immulite 1000, Siemens). The intra-assay 
coefficient of variation was less than 5% for all parameters.
For measurement of plasma levels of total FFAs (C12-
C24) including palmitic acid (PA, C16:0), sample prep-
aration and detection of fatty acid methyl esters was 
performed according to the method of Bicalho et  al [53] 
using gas chromatography/mass spectrometry (Agilent 
Technologies, 7890 B) with a coefficient of variation less 
than 5% as well.
3-Tesla 1H-Magnetic Resonance Spectroscopy 
for Measurements of Intramyocellular Lipid and 
Extramyocellular Lipid
The 1H-MRS scans of IMCL and EMCL were obtained by 
the 3-T MR scanner Siemens Magnetom Trio at around 
maximal convexity of the right vastus lateralis muscle (on 
maximal knee extension) at 7  am in overnight-fasted su-
pine participants in a head-out position. Post-CPAP remeas-
urement was located 5 cm proximal or distal (at random 
order) of the pre-CPAP measurement to avoid interference 
with the first muscle biopsy (see the following sections). The 
spectra were acquired using a single-voxel spectroscopy 
(SVS, repetition time: 2000 ms; echo time: 20 ms; averages: 
176; volume of interest: 20 × 20 × 20 mm3; TM: 10 ms; flip 
angle: 90°; water saturation; shimming < 40 Hz full width 
half maximum. All spectra were analyzed and postprocessed 
by JMRUI (v5), Amares (http://www.jmrui.eu). The fol-
lowing substances were identified: IMCL (1.3 ppm), EMCL 
(1.5 ppm), and creatine (3.03 ppm). The IMCL and EMCL 
signals were normalized for the creatine signal.
1.5-T Magnetic Resonance Tomography for 
Volugraphy of Thigh Subcutaneous Fat Volume
The total ScFAT of the right thigh was quantified between 
the trochanter minor and the upper patella margin by a 
1.5-T whole-body MR scanner (Siemens Espree). The im-
ages were acquired using a T2 turbo-spin-echo sequence 
(TSE, repetition time = 5490 ms, echo time = 91 ms, slice 
thickness = 4.0 mm, interslice gap = 0%) with composing 
algorithm: spine (syngo MR B17). The software OSIRIX 
(OSIRIX v.6.0.2 32-bit, Pixmeo) with segmentation plugin 
(Segmentation 1.0.xr plugin, Chimaera GmbH) was used 
for the volugraphy of ScFAT in all volunteers.
Skeletal Muscle Fiber Histomorphology and 
Composition
In 25 OSA patients and 20 controls muscle biopsies were 
obtained from the vastus lateralis muscle at the exact site of 
1H-MRS by conchotome technique through an 8-mm skin 
and fascia incision after local anesthesia and disinfection, 
immediately shock-frozen in liquid N2-cooled isopentane, 
and stored at –80 °C. Transverse 7 µm-cryosections (cryo-
stat microtome Hyrax C60, Carl Zeiss AG) were used for 
histochemical identification of fiber type 1, 2a, or 2x using 
the acid-sensitive myofibrillar adenosine triphosphatase 
(ATPase) staining (adenosine triphosphatase, Sigma-
Aldrich Co LLC) after preincubation at pH 4.6 (5 min-
utes, room temperature) as previously described [54]. 
Fiber-type–specific cross-sectional area and composition 
(percentage of type 1, 2a, and 2x fiber count and overall 
area) were analyzed in rectangular tissue areas with 
more than 100 fibers by applying ImageJ (Scion Image, 
National Institutes of Health) to digitized images with 
200-fold magnification obtained by the Zeiss Axio Imager.
M2 microscope (Carl Zeiss AG combined with Axio-Cam 
HRc/AxioVision,).
Statistics
Continuous variables were presented as means ± SEM for 
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(before and after CPAP treatment) as well as for their 
nonobese and obese strata. Cross-sectional analyses of 
the separate impact of untreated OSA, OBS, or their inter-
action were performed by 2-factorial analysis of variance 
(ANOVA). The unpaired t test or, whenever adequate ac-
cording to a Kolmogorov-Smirnov test within groups and 
strata, the Mann-Whitney U  test was used (post hoc) to 
detect significant differences between groups or strata. 
Significant OSA- and OBS-related differences were in-
dicated by the symbols “*” and “#,” respectively, in the 
figures (for tables see legends). The t test for paired obser-
vation was used to assess significant individual changes 
pre- and post-CPAP treatment (indicated by §), in the 
figures (for tables see legends). Bivariate correlations 
between individual parameters (eg, between FFAs and 
AHI) were described by scatter plots with identification 
of groups and strata, regression line, Pearson correlation 
coefficient r, and corresponding P values or presented by 
r and P values in the text. Multivariable regression was 
used to evaluate the contribution of likely relevant fac-
tors to IMCL (and EMCL), for example, by combining 
the factors total FFAs (minus PA) and PA plasma levels 
together with ScFAT (or BMI). To illustrate overall predic-
tion of IMCL by contributors identified to be independent 
and significant, IMCL (y-axis) was plotted against the 
predictive term (x-axis) derived from the multivariable re-
gression equation together with the regression line and in-
dication of multiple r and P values. A P level less than .05 
was considered statistically significant. Owing to the ex-
ploratory rather than confirmatory use of statistical ana-
lysis, no Bonferroni correction was used. SPSS software 
version 22.0 (IBM) was used for all statistical procedures.
Results
Cross-Sectional Comparison at Baseline
In general, the anthropometric parameters (see Table 1, 
P values of 2-factorial ANOVA on the right side) were 
similar between the total group of OSA patients and con-
trol participants and between their respective nonobese or 
obese strata. However, owing to their rare eligibility, the 
9 nonobese OSA patients had a significantly (by 7.2 and 
5.2  years) higher age than nonobese controls and obese 
OSA patients, respectively. The total thigh ScFAT showed 
no significant difference between OSA and controls; it 
was, however, significantly affected by OBS. OSA patients 
showed an AHI between 15.1 and 94.2 h–1. They were ex-
posed to a significantly longer Tu90% (64.5 ± 15.0 min-
utes; controls: 1.86 ± 0.79 minutes) and a significantly 
(by 1.2%) lower mean SaO2. OSA was associated with a 
moderately but significantly higher systolic and diastolic 
blood pressure, with the latter also being affected by OBS, 
whereas higher cIMT was attributable solely to OSA. 
Moreover, OSA was associated with a moderate but sig-
nificant increase in HbA1c, whereas fasted glucose, insulin, 
and HOMA-IR-index were increased both with OSA and 
OBS. Circulating plasma TNF levels showed no OSA- or 
OBS-related differences. Within the lipid profile, increased 
plasma triglyceride levels were associated with OSA, espe-
cially in the nonobese strata, whereas total cholesterol was 
lower with OBS as detectable within controls. There was 
a significant increase in plasma levels of FFAs (by 178%) 
and PA (by 166%) with OSA but not with OBS (see Table 
1, Figure 1 upper panel) with these increases being more 
accentuated in the nonobese (by 236% and 246%) than in 
the obese (by 146% and 122%) strata.
As a main finding, IMCL and EMCL were found to be 
significantly, by approximately 55% and 40%, respectively, 
higher in the total group of OSA as compared to the control 
group (Figure 2, see Table 1). Thereby, notably, the nonobese 
OSA patients showed massive increases of IMCL (114%) 
and EMCL (103%) compared to their nonobese controls. 
In contrast, in obese OSA patients increases of 24.4% and 
8.4%, respectively, were observed compared to their obese 
controls, notably, with prevailing high IMCL and EMCL. 
The overall impact of OBS on IMCL and EMCL did not 
Figure 1. Upper panel: Total free fatty acid (FFA) plasma levels be-
tween 7  am and 9  am in obstructive sleep apnea (OSA) patients and 
healthy control individuals and their nonobese and obese strata. Mean 
values ± SEM, *P less than .05; **P less than .01 OSA vs control. Lower 
panel: Correlation of total FFA plasma levels to apnea-hypopnea index 
(AHI) within the total study population with indication of the individual 
assignment to the 2 groups, OSA and controls, and their nonobese or 
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reach significance but obviously increased IMCL by 95% 
(P < .05) and EMCL by 66% (P > .05) in obese compared 
to nonobese OSA-free control participants. Thereby, inter-
estingly, no significant additional (or interactive) muscular 
lipid accumulation arose from OBS within the group of 
OSA patients according to ANOVA (see Figure 2, Table 1).
While VO2max in absolute terms was significantly re-
duced solely with OSA, VO2max normalized to body 
weight was also lower with OBS in addition to OSA and 
there was an interaction of OSA and OBS with both these 
parameters. Lower physical activity per week was found to 
be associated with OSA and OBS (see Table 1).
Skeletal muscle histomorphometry in biopsies largely 
excluded any significant impact of the factors OSA or OBS 
on type-specific fiber fraction (see Table 2). However, owing 
to enlarged fiber size, a significantly larger fractional area 
of type 2x fiber was observed with OBS, which correlated 
with BMI (r = 0.38, P = .01), likely reflecting some mus-
cular adaptation to implicit body weight–related training.
Correlations at Baseline
There were significant correlations of total FFAs and of 
PA to AHI (r = 0.455, P < .01 and r = 0.445, P < .01, re-
spectively; see Figure 1 lower panel) as well as to Tu90% 
(r = 0.415, P < .05 and r = 0.407, P < .05, not shown), but 
not, however, to BMI (r = 0.076, P > .604 and r = 0.066, 
P = .661) within the total study population. IMCL and 
EMCL were overall unrelated to AHI (r = 0.18, P = .210 
and r = 0.20, P = .168, respectively). There was, however, 
a correlation between IMCL and Tu90%, which indi-
cates cumulative hypoxic stress (r = 0.331, P = .042), but 
not between EMCL and Tu90% (r = 0.319, P = .051). In 
addition, IMCL but not EMCL was significantly related 
to BMI (r = 0.333, P = .019) and to ScFAT (r = 0.447, 
P = .002). Within the nonobese strata, the IMCL and 
EMCL both were considerably closer correlated to AHI 
(r = 0.590, P = .006 and r = 0.446, P = .049, respectively) 
and to Tu90% than the obese strata. At the same time, the 
obese strata showed a closer correlation between IMCL 
and ScFAT (r = 0.534, P = .004) than the nonobese strata. 
A positive correlation between IMCL and plasma levels 
of total FFAs or of PA existed within the nonobese strata 
(r = 0.606, P = .005 or r = 0.642, P = .003, respectively), 
but not within the obese strata or the study population in 
Figure 2. 1H-magnetic resonance spectroscopy (1H-MRS, 3 Tesla) of 
intramyocellular and extramyocellular lipid (IMCL and EMCL) accumu-
lation in the right vastus lateralis muscle at 7 am of overnight fasted 
obstructive sleep apnea (OSA) patients compared to healthy control 
individuals. A, Localization of the 1H-MRS voxel within an MR tomo-
graphic image obtained at maximal convexity of the vastus lateralis 
muscle was marked for muscle biopsy. B, 1H-MR spectrum with peaks 
relating to IMCL (1.3 ppm), EMCL (1.5 ppm), and creatine (3.03 ppm). 
C and D, Mean ± SEM IMCL and EMCL values, respectively, presented 
for the 2 groups of OSA patients and control individuals (left) and 
their respective nonobese (middle) and obese strata (right). Mean 
values ± SEM, *P less than .05; **P less than .01 OSA vs control; # P 
less than .05, obese vs nonobese strata. For 2-factorial analysis of vari-
ance, see Table 1 and “Materials and Methods.”
Table 2. Vastus lateralis muscle fiber composition of untreated obstructive sleep apnea patients and controls as well as their 
respective nonobese and obese strata
 All Nonobese Obese
ANOVAControls OSA Controls OSA Controls OSA 
No.  20 25 10 8 10 17 45
Fiber count fraction—type 1 % 39.5 ± 3.1 40.6 ± 2.4 41.7 ± 4.5 36.3 ± 4.0 37.3 ± 4.3 42.6 ± 2.9  
Fiber count fraction—type 2a % 31.5 ± 3.6 29.0 ± 1.9 35.5 ± 6.1 32.6 ± 3.5 27.6 ± 3.6 27.3 ± 2.2  
Fiber count fraction—type 2x % 29.0 ± 3.0 30.8 ± 2.2 22.7 ± 3.9 31.1 ± 3.9 35.3 ± 3.6 30.6 ± 2.8  
Fractional area—type1 % 39.3 ± 3.2 39.6 ± 2.3 41.8 ± 4.7 36.3 ± 4.4 36.8 ± 4.4 41.1 ± 2.6  
Fractional area—type 2a % 34.6 ± 3.7 30.3 ± 2.1 38.8 ± 6.4 35.9 ± 3.9 30.4 ± 3.7 27.7 ± 2.3  
Fractional area—type 2x % 26.1 ± 2.9 30.1 ± 2.1 19.3 ± 3.3 27.8 ± 3.0 32.8 ± 3.8 31.2 ± 2.8 a
Data represent mean ± SEM. No significant differences between groups or strata were detected by the unpaired t  test or, whenever adequate, the Mann-
Whitney U test. Overall, ANOVA detected a significant impact of obesity (aP < .05) on fractional area of type 2x fibers.
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total. In the nonobese strata, EMCL also showed signifi-
cant correlations to plasma levels of total FFAs and PA 
(r = 0.675, P = .002 or r = 0.703, P = .001); the correl-
ations were also significant within the total study popu-
lation. Moreover, the nonobese, but not the obese strata, 
showed a significant positive correlation between IMCL 
and plasma levels of triglycerides (r = 0.448, P = .047). 
Regarding muscle histology, IMCL or EMCL were un-
related to type 1 fiber fraction (% count or % area), ex-
cept for a significant negative correlation between EMCL 
and % type 1 fiber count. Furthermore, there was a sig-
nificant negative correlation between both IMCL and 
EMCL to VO2max per kg body weight within the total 
study population and the nonobese strata.
To explore factors predominantly contributing to high 
IMCL, we conducted a multivariable regression analysis 
considering the aforementioned factors given. The inclusion 
of 1) PA and 2) total FFAs (minus PA) plasma concentration 
(affected by OSA, ie, related to AHI) on the one hand and 
3) ScFAT (affected by OBS, ie, related to BMI: r = 0.765, 
P < .001) on the other hand into the regression equation 
yielded a multiple r = 0.568 (P = .002) for IMCL prediction 
within the total study population with a significant inde-
pendent contribution of each of the factors 1)  (P = .013), 
2) (P = .016) and 3) (P = .001) (Figure 3; for multivariable 
predictive term see the x-axis: –2.121 + 0.015 * PA-0.004 * 
FFAs minus PA + 4.449 * ScFAT). Thereby, importantly, an 
inclusion of the 3 potential (bias) factors VO2max, age, and 
type 1 muscle fiber fraction (alone or combined) into the 
regression equation yielded no significant independent con-
tribution to IMCL, that is, no improved prediction. When 
applying this regression approach to the nonobese strata 
(with high OSA-related FFA and PA increases) solely, a 
stronger prediction of IMCL was found (multiple r = 0.853, 
P = .002), with a significant contribution for each of these 
factors 1)  (P = .007), 2)  (P = .013), and 3)  (P = .032), 
respectively (multivariate predictive term: –8.881 + 0.017 * 
PA-0.004 * FFAs minus PA + 6.712 * ScFAT, not shown). 
Again, VO2max per kg body weight, age, and/or muscle 
histology had no significant additional impact (bias) on 
inclusion into the regression equation. Notably, replacing 
ScFAT by BMI in the regression equation yielded a slightly 
weaker prediction within the total study population (mul-
tiple r = 0.425, P = .034; factor 1): P = .060, 2): P = .062, 
and 3): P = .016) and within the nonobese strata (multiple 
r = 0.775, P = .003; factor 1): P = .009, 2), P = .019, and 
3): P = .770).
In case of EMCL multivariate regression approach 
including these 3 variables, that is PA, FFAs (minus PA), 
and ScFAT, resulted in a prediction with a multiple of 
r = 0.529 (P = .006) in the total study population with the 
independent contribution of each the factors 1) (P = .038), 
2) (P = .060), and 3) (P = .022), respectively (not shown).
Overall, HbA1c showed no significant bivariate cor-
relation to IMCL (r = –0.178, P = .226) or to VO2max 
(r = 0.260, P = .085). Interestingly, however, HbA1c was sig-
nificantly positively related to IMCL (r = 0.593, P = .006) - 
beside being negatively related to VO2max (r = −0.522, 
P = .022) - within the nonobese participants, whereas 
within the obese strata, HbA1c showed a significant nega-
tive correlation to IMCL (r = –0.400, P = .035). According 
to an explorative multivariable regression including all par-
ticipants, the combination of IMCL and VO2max resulted 
in a multiple r = 0.428 (P = .014) with significant contribu-
tions of both factors (P = .019 and P = .009, respectively). 
The HbA1c prediction was improved by inclusion of AHI 
(multiple r = 0.589, P = .001), while BMI or age made no 
significant contribution to the prediction.
Notably, VO2max per body weight was found to be related 
to OSA severity in terms of AHI (r = –0.335, P = .026) as well 
as to OBS in terms of BMI (r = –0.542, P = .000) or ScFAT 
(r = –0.579, P = .000) (see also ANOVA, Table 1). Regarding 
vascular risks through OSA, we noted a correlation be-
tween cIMT and IMCL (r = 0.37, P = .011), EMCL (r = 0.35, 
P = .017), AHI (r = 0.34, P = .023), and Tu90% (r = 0.42, 
P = .003). There was a highly significant, close correlation be-
tween IMCL and EMCL within the total study population 
(r = 0.73, P = .000) as well as within the groups or strata.
Effect of Continuous Positive Airway 
Pressure Therapy
Several months of CPAP (4.3 ± 0.5 hours per night, in 
4 nonobese and 10 obese patients) improved AHI and 
Tu90%, and mean SaO2 (Table 3), not only compared to the 
pretreatment status but also compared to the healthy con-
trol group (see Table 1). Although CPAP treatment had no 
Figure 3. Scatter plot representing explorative multivariable predic-
tion of intramyocellular lipid (IMCL) (y-axis) by the combination of total 
fatty acid (FFA) and palmitic acid (PA) as well as thigh subcutaneous 
fat volume (ScFAT) according to regression analysis (x-axis) within the 
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significant effect on BMI or ScFAT, it significantly lowered 
heart rate—a bona fide marker of resting sympathetic 
activity—by more than 6  beats/min (P = .034, Table 3) 
Moreover, patients on CPAP showed a trend toward lower 
systolic and diastolic blood pressure (–6 mm Hg) as well 
as reduced cIMT. Notably, CPAP failed to significantly im-
prove HbA1c, postabsorptive glucose, insulin, HOMA-IR, 
TNF, as well as lipid plasma levels. The total FFAs and PA 
plasma levels were found to decrease nonsignificantly by 
27% and 24%, respectively, on CPAP therapy. There was a 
concomitant trend toward decreased IMCL (–22% overall, 
–37% in nonobese, –16% in obese) and a significant reduc-
tion in EMCL (–26% overall, –25% in nonobese, –27% 
in obese) with CPAP treatment (Fig. 4). For comparison, 
a complete reversal of OSA-induced IMCL and EMCL 
through CPAP to respective control levels (in terms of per-
centage of levels in OSA patients, Table 1) would require 
IMCL to decrease by –36% overall, by –54% in nonobese, 
and by –20% in obese patients. EMCL would need to de-
crease by –28% overall, by –51% in nonobese, and by –8% 
in obese patients. Thus, CPAP only partly reversed IMCL 
but completely reversed EMCL at least in obese patients.
Notably, CPAP significantly changed neither VO2max 
per body weight (P = .058) nor the amount physical ac-
tivity in OSA patients, which might have been due to the 
small number of volunteers enrolled. Furthermore, none of 
the histomorphological parameters of the vastus lateralis 
muscle biopsies were affected by CPAP.
Discussion
The present 3-T 1H-MRS study, which, notably, was con-
ducted in the early morning (7 am), provides first evidence 
that moderate to severe OSA is independently of OBS asso-
ciated with significant increases both of IMCL and EMCL 
in the vastus lateralis muscle as compared to healthy 
controls with exclusion of these OSA grades. Importantly, 
substantial OSA-related increases of IMCL and EMCL may 
occur especially in nonobese OSA, since healthy obese in-
dividuals tend to have already increased IMCL and EMCL 
[43]. Moreover, in line with a hypothesis, that OSA- that 
is, CIH-related lipolysis may increase circulating FFAs and 
thus contribute to high IMCL [38-40], we presently dem-
onstrate that total FFAs and especially PA (as a factor of 
IR in healthy humans [41, 42]) i) are significantly increased 
with OSA (see Table 1, Figure 1) and ii) significantly cor-
relate with AHI as a measure of OSA severity (see Fig. 1). 
Furthermore, total FFAs (minus PA) and PA plasma levels 
both contribute significantly and independently of each 
other to the IMCL (multiple r = 0.568, P = .002) when 
controlled for thigh ScFAT as a measure of OBS. Replacing 
ScFAT by BMI, which reflects both fat and muscle mass, 
Table 3. Effect of continuous positive airway pressure on sleep parameter, resting heart rate, and aerobic capacity
 Pre-CPAP Post-CPAP
No. 14 14
AHI h–1 49.4 ± 7.2 3.7 ± 1.4c
Time < 90% SaO2 min 75.4 ± 25.4 8.7 ± 7.1
a
Mean SaO2 % 92.1 ± 0.6 94.6 ± 0.4
b
Heart rate at rest min–1 72.5 ± 2.5 65.9 ± 2.1a
VO2max/kg body wt mL min
–1 kg–1 29.8 ± 2.2 25.2 ± 1.3
Data represent mean ± SEM
Abbreviations: AHI, apnea-hypopnea index; CPAP, continuous positive airway pressure; SaO2, oxygen saturation; VO2max, maximal oxygen uptake.
aP less than .05; bP less than .01; cP less than .001 by paired t test comparing post- vs pre-CPAP values.
Figure 4. Effect of 3 to 5 months of home-based continuous positive 
airway pressure (CPAP) on intramyocellular lipid (IMCL) (upper panel) 
and extramyocellular lipid (EMCL) (lower panel) in vastus lateralis 
muscle of 14 obstructive sleep apnea patients. Mean ± SEM of pre- 
and post-CPAP values are presented for the total group (left) and its 
nonobese (middle) as well as its obese stratum (right). § for P less than 
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still resulted in significant correlation (multiple r = 0.425, 
P = .034). In either approach, there was no significant in-
dependent influence (ie, bias) of age, VO2max, or muscle 
histology to explain IMCL variability.
When we considered the nonobese strata alone, the 3 
factors, that is, FFAs (minus PA) and PA plasma levels as 
well as ScFAT gave an improved multivariate IMCL predic-
tion (multiple r = 0.853, P = .002) whereby each parameter 
showed a significant independent contribution. Including 
the more readily available BMI instead of ScFAT in the re-
gression equation resulted in significant multivariate pre-
diction as well (multiple r = 0.775, P = .003).
The present evidence from CPAP treatment for a causal 
role of OSA in increased IMCL and EMCL should be con-
sidered as preliminary, because only EMCL, not however, 
IMCL, FFA, and PA were significantly reduced. A distinct 
weakness of the study was the small size of the treatment 
group, the short duration of treatment applied with the usual 
poor adherence, and the lack of a sham intervention group. 
However, the trends observed may warrant further studies.
Notably, OSA-related lipolytic increases in plasma FFAs 
and in IMCL (and EMCL) may be massive but transient 
[39], that is, detectable only shortly after overnight CIH 
stress. In the course of the day they may subside depending 
on metabolic demand and activity [52]. This point may, at 
least in part, explain previous negative studies on IMCL in 
OSA patients [50, 51]. The rapid decrease in FFAs between 
7 am and 10 am, as reported in untreated OSA patients [39], 
may have contributed to the rather large variability in FFAs 
(and IMCL) presently observed within this time interval.
Interestingly, there was a massive increase in plasma tri-
glycerides with OSA that occurred especially in nonobese 
participants (214.7 ± 40.9 vs 95.6 ± 12.6  mg 100  mL–1), 
suggesting that overnight increases in circulating FFAs 
may exceed muscle or liver uptake capacity and may there-
fore be associated with re-esterification of FFAs (FFA-
triacylglycerol recycling). Diurnal variations in FFAs and 
IMCL in OSA patients should therefore be considered in 
future studies.
Another important confounding factor of IMCL (and 
EMCL) obviously is OBS itself [43] as presently indicated 
by a trend toward higher IMCL in obese than in nonobese 
healthy controls. Interestingly, the combination of OBS 
with OSA yielded no essential further increase in IMCL 
or EMCL, which implies that the effect of OSA on IMCL 
or EMCL or its reversal by CPAP may be confounded by 
prevailing OBS. This interference of OBS was controlled 
for by our multivariable regression analysis in our study. 
Our data indicated that ScFAT or BMI, along with FFAs, 
made significant contributions to the prediction of IMCL 
and EMCL within the total study population. As a study 
limitation, our analysis was limited to BMI and ScFAT and 
could not assess the potentially more critical role of truncal 
fat distribution for IMCL and EMCL in OSA. In view of 
the high OSA prevalence in obese participants, it remains to 
be seen to what extent well-documented increases in IMCL 
with OBS may be in fact attributable to OSA not previously 
taken into consideration [43].
The “lipotoxic” role of increased IMCL in IR has been 
extensively discussed and reviewed and appears not to be 
uniformly applicable because of factors like OBS, physical 
activity (“athlete paradox”), as well as dynamic metab-
olism of triacylglycerides and diacylglycerides including 
ceramide formation [55]. Since our study did not contain 
a gold-standard parameter for peripheral IR, the potential 
muscular metabolic contributions to HbA
1c in the total 
study population were examined in a hypothesis-generating 
manner: We were able to show by multivariable regression 
that IMCL and VO2max with (multiple r = 0.589, P = .001) 
or without (r = 0.428, P = .014) AHI were significant fac-
tors for the prediction of HbA1c, whereas BMI or age made 
no significant contributions. Thereby, notably, the bivariate 
correlation of HbA1c to IMCL was positive in nonobese 
(r = 0.593, P = .006), but negative in obese participants 
(r = –0.400, P = .035), which may not generally support a 
monocausal lipotoxic concept of IMCL as a missing link 
between OSA and IR [38, 41, 42] and warrants further 
studies regarding other relevant metabolic factors [55]. The 
significant role of VO2max (reduced both with OSA and 
OBS) may point at inactivity-related factors such as endo-
thelial dysfunction, capillary rarefication (in case of OBS 
[56]), or other reported factors of IR [49, 57] not presently 
determined. It is important, however, that with our results 
we could largely rule out a role for changes in skeletal 
muscle fiber composition, in particular changes in the type 
1 fiber fraction, which would affect IR [57], for example, 
via mitochondrial capacity. Notably, however, there was an 
OBS-related significant increase in type 2x fiber fractional 
area that may require consideration in future studies on IR 
in obese and nonobese OSA patients (see Table 2).
Moreover, the present data suggest that accumula-
tion of EMCL (ie, intermyocellular or perimuscular/peri-
vascular fat) may similarly be attributable to increased 
total FFAs, PA, and ScFAT (multiple r = 0.529, P = .006). 
Interestingly, EMCL has been suggested to contribute to 
IR as well: Dietary lipid overload or OBS leads to skel-
etal muscle infiltration of inflammatory macrophages and 
T cells (stimulated by factors like monocyte-chemotactic-
protein-1 (MCP1 = CCL2), CD11a or palmitate) that is 
clearly related to IR in humans as well as in animal models 
[47, 48, 58-62]. Such inflammation (along with endothelial 
lipid accumulation) may contribute to a microvascular, that 
is, a nonmyocellular cause of IR, such as impaired insulin-
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both of which delay glucose uptake of skeletal muscle [49, 
63]. Skeletal muscle IR may even be predicted by perivas-
cular fat at the site of large conduit arteries [64].
In summary, the present 3-T 1H-MRS study observed 
significant increases in the early morning of circulating 
FFAs and of IMCL and EMCL that appear to be inter-
related and all attributable to OSA rather than to OBS 
(controlled for by ScFAT or BMI). The correlation of FFAs 
and especially PA to the severity of OSA (AHI) in combin-
ation with a CPAP treatment effect, at least on EMCL, sup-
ports the part of the concept of Gu et al [38] that dynamic 
increases in circulating FFAs lead to ectopic lipid accu-
mulation with OSA [39, 40]. As possible triggers for ec-
topic lipid accumulation, the role of sympathetic activation 
through repeated hypoxic (and hypercapnic) stimulation of 
peripheral chemoreceptors (which tend to be hypersensi-
tive with OSA [2]) and the role other lipolytic factors such 
as elevated cortisol levels warrant further studies. Whether 
there is a role of high IMCL and inactivity-related factors 
determining VO2max for IR, as presently suggested by the 
association with HbA1c, requires studies with gold-standard 
IR measurements.
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